Los Angeles Capital Management
ALDX icon

Los Angeles Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Los Angeles Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,320
Closed -$62.5K – 1355
2025
Q2 		$62.5K Buy
+16,320
New +$42.2K ﹤0.01% 1288
2024
Q4 		– Sell
-271,262
Closed -$1.46M – 1104
2024
Q3 		$1.46M Sell
271,262
-63,407
-19% -$302K 0.01% 536
2024
Q2 		$1.11M Sell
334,669
-46,104
-12% -$181K ﹤0.01% 629
2024
Q1 		$1.25M Buy
380,773
+269,061
+241% +$885K ﹤0.01% 623
2023
Q4 		$392K Buy
+111,712
New +$345K ﹤0.01% 943

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Los Angeles Capital Management's ALDX Position: Q3 2025 in Review

Los Angeles Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q3 2025, closing a stake of 16,320 shares — an estimated $62.5K sold.

Los Angeles Capital Management first reported a position in ALDX in Q4 2023 and held it in 5 quarters. The position peaked at $1.46M in Q3 2024. 130 funds tracked by Wall St. Rank hold ALDX as of Q3 2025.

  • Los Angeles Capital Management reported no remaining Aldeyra Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Los Angeles Capital Management sold 16,320 Aldeyra Therapeutics shares in Q3 2025, an estimated $62.5K.
  • Los Angeles Capital Management first reported a position in Aldeyra Therapeutics in Q4 2023 and held it in 5 quarters.
  • Los Angeles Capital Management's Aldeyra Therapeutics position peaked at $1.46M in Q3 2024.
  • 130 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2025.

Based on Los Angeles Capital Management's 13F filing for Q3 2025, filed 20 Oct 2025.